As a scientist researching how to combat the courage of cancer, Clay B. Siegall, Ph.D. has impeccable credentials. Siegall received a Ph.D in Genetics from George Washington University, then went to work for the Institute of Cancer of the National Institutes of Health. From there, Bristol-Myers Squibb Pharmaceutical Research Institute snatched him up, and he looked into the possibility of fighting cancer using monoclonal antibodies. Siegall co-founded Seattle Genetics in 1997. He worked his way up the chain of command, and is now President, Chairman of the Board and CEO.
And he has turned Seattle Genetics into a pioneering leading of antibody-drug-conjugates (ADC) technologies. In 2011, the Food and Drug Administration approved their first drug ADCETRIS® (brentuximab vedotin). Siegall and Seattle Genetics have partnered with Takeda Pharmaceutical Company to sell that drug for cancer treatment in over 60 countries. Plus, they have partnered with other major pharmaceutical companies to develop over 20 other drugs, which are in the development pipeline now.
Besides his duties with Seattle Genetics, Siegall serves on the board of directors of other biotechnology companies: Alder BioPharmaceuticals, Ultragenyx Pharmaceutical, Washington Roundtable and Mirna Therapeutics. He holds 15 patents and published over 70 articles. In 2013 the University of Maryland named him alumnus of the year for the College of Computer, Mathematical and Natural Sciences.
Siegall’s Facebook page is a mix of the personal and the professional. As do many busy company CEOs, much of his social life appears to be related to his activities as a cancer fighter and company president. For instance, a woman named Laura mentioned Siegall in a Facebook post because her daughter toured the premises of Siegall’s company, Seattle Genetics, with him. Siegall was nice enough to pose for a picture with the little girl. Siegall appears in a photograph with another man, in connection with the annual Bioscience Day at the College of Computer, Mathematical and Natural Sciences of the University of Maryland at College Park, where he is an alumnus of the class of ’82 with a degree in zoology.